查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534903

羟考酮市场：现况分析与预测（2024-2032）

Oxycodone Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 134 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

在预测期（2024-2032年），羟考酮市场预计将以 5.13%的年复合成长率显着成长。这可能是因为人口老化以及关节炎和腰痛等慢性疼痛的发生率不断增加，这也增加了对羟考酮等鸦片类止痛药的需求。美国国立卫生研究院（NIH）（.gov）在一份报告中指出，到2023年，慢性疼痛新发病例将达到每年每 1000 人 52.4 例的高水准。相较之下，其他常见慢性疾病如糖尿病（7.1例/1000人/年）、忧郁症（15.9例/1000人/年）和高血压（45.3例/1000人/年）。此外，对羟考酮的需求增加导致製造和销售该药物的製药公司收入增加。

依类型，市场分为长效羟考酮和短效羟考酮。2023年，长效羟考酮将占据市场。它主要适用于患有慢性疼痛（例如关节炎、癌症或严重背痛）的患者，这些患者需要长期缓解疼痛才能过上美好的生活。羟考酮的易用性和效率会影响处方者选择它而不是其他形式的鸦片类药物，提高处方率。

根据应用，市场分为疼痛管理和戒瘾。到2023年，疼痛管理将占据压倒性的市场。关节炎、纤维肌痛和神经性疼痛等慢性疾病的盛行率不断上升，也增加了对止痛产品的需求，创造了对羟考酮的需求。例如，在美国（NHIS），2019年至2021年，大约5.4%的18 岁至44 岁成年人报告患有关节炎，而在45 岁至64 岁的成年人中，四分之一（26.0%）报告指出患有关节炎。此外，随着阿片类药物在疼痛管理中的使用增加，以及人们对控制疼痛以改善患者治疗效果的认识不断提高，羟考酮等鸦片类药物现在比以往任何时候都更容易获得和使用。

根据通路，市场分为医院药房、零售药房和网路药房。预计在预测期内（2024-2032年），医院将以显着的年复合成长率成长。由于慢性和急性病症的手术和住院治疗的增加，医院环境中对充分缓解疼痛的需求也在增加，增加了对羟考酮的需求。例如，根据世界卫生组织（WHO）表示，到2023年，全球每年将进行超过 3亿例外科手术。此外，医院药局提供了一个重要的介面，以教育患者如何正确使用鸦片类药物的处方剂量并避免滥用风险。

为了更了解羟考酮的市场介绍，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、法国、英国、西班牙、义大利、欧洲其他地区）、亚太地区（中国、日本、印度和其他亚太地区）、以及世界其他地区。随着亚太地区目前经济成长，医疗设施日益发达，包括疼痛管理在内的治疗方法也越来越多。亚太地区的药品生产也在成长，有多家国内和跨国公司参与生产和销售鸦片类药物。因此，随着癌症、糖尿病等慢性疼痛疾病的出现以及人口老化，中国、印度和日本是受影响最严重的国家。

市场上营运的主要公司包括Purdue Pharma L.P.、Johnson &Johnson Services, Inc.、Teva Pharmaceutical Industries Ltd.、Endo, Inc.、Mallinckrodt company、Lannett、Pfizer Inc.、Amneal Pharmaceuticals LLC、Indivior PLC、Teikoku Seiyaku Co., Ltd.。

目录

第1章 市场介绍

  • 市场定义
  • 主要目的
  • 利害关係人
  • 限制

第2章 研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第3章 执行摘要

  • 行业概况
  • 依细分市场进行预测
    • 市场成长强度
  • 区域展望

第4章 市场动态

  • 促进因素
  • 机会
  • 抑制因素
  • 趋势
  • PESTEL 分析
  • 需求方分析
  • 供给面分析
    • 併购
    • 投资场景
    • 产业洞察：主要新创公司及其独特策略

第5章 价格分析

  • 区域价格分析
  • 影响价格的因素

第6章 全球羟考酮市场收入，2022-2032

第7章 依类型划分的市场分析

  • 长效羟考酮
  • 短效羟考酮

第8章 应用市场分析

  • 疼痛管理
  • 戒瘾

第9章 依通路划分的市场分析

  • 医院药房
  • 零售药局
  • 网路药局

第10章 依地区划分的市场分析

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第11章 价值链分析

  • 边际分析
  • 进入市场的公司名单

第12章 竞争态势

  • 竞争仪表板
  • 竞争市场定位分析
  • 波特五力分析

第13章 公司简介

  • Purdue Pharma L.P.
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Endo, Inc.
  • Mallinckrodt company
  • Lannett
  • Pfizer Inc.
  • Amneal Pharmaceuticals LLC
  • Indivior PLC
  • Teikoku Seiyaku Co.,Ltd.

第14章 首字母缩写与先决条件

第15章 附录

简介目录
Product Code: UMHE212902

Oxycodone is a potent opioid pain medication used to relieve moderate to severe pain. It works in the brain to change how your body feels and responds to pain. Oxycodone is often prescribed in extended-release forms for around-the-clock pain relief. This is due to its nature of being commonly abused and having addictive properties which is a controlled substance. Further, the existing opioid crisis has raised concerns about the opioid class of drugs, including Oxycodone, which may alter regulatory control and usage patterns. Moreover, the growing trend in the use of non-opioid and different pain management practices may have an impact on oxycodone demand in the future.

The Oxycodone Market is expected to grow with a significant CAGR of 5.13% during the forecast period (2024-2032). This can be attributed to the rising geriatric population coupled with the incidence of such chronic pain conditions as arthritis and back pain, and, therefore, the need for Opioid pain relievers like oxycodone also rises. The National Institutes of Health (NIH) (.gov) stated in the report that in 2023, new chronic pain cases were high, at 52.4 cases per 1,000 persons per year. This is compared to other common chronic conditions, such as diabetes (7.1 cases/1,000 per year), depression (15.9 cases/ 1,000 per year), and hypertension (45.3 cases/1,000 per year). Additionally, the growing demand for oxycodone has led to increased revenue for pharmaceutical companies producing and selling this medication.

Based on the type, the market has been divided into long-acting oxycodone and short-acting oxycodone. The long-acting oxycodone held a dominant share of the market in 2023. This is mainly helpful for those patients suffering from chronic pain like arthritis, cancer, and severe back pain that need long-term pain relief for them to have a good life. The ease and efficiency of using oxycodone have influenced prescribers to choose it over other forms of opioids, thus raising prescription rates.

Based on the application, the market is segmented into pain management and de-addiction. The pain management held a dominant share of the market in 2023. The rise in the prevalence of chronic illnesses like arthritis, fibromyalgia, and neuropathic pain has also contributed to the demand for pain relief products, which in turn has created the demand for oxycodone. For instance, from 2019 to 2021 in the United States (NHIS), around 5.4% of adults 18 to 44 years old reported arthritis, and Among adults aged 45 to 64 years, one-in-four (26.0%) reported doctor-diagnosed arthritis. Furthermore, improvements in the utilization of opioids for pain management and increasing awareness of the need to manage pain to enhance patient outcomes have made opioids such as oxycodone more accessible and appropriately used than in the past.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospitals are expected to grow with a significant CAGR in the forecast period (2024-2032). The higher incidence of surgeries and hospitalizations resulting from chronic and acute illnesses has also created a higher need for adequate pain relief in hospital environments, hence the need for oxycodone. For instance, according to the World Health Organisation, in 2023, over 300 million surgical procedures were performed each year worldwide. In addition, the hospital pharmacy provides an essential interface for educating patients about the proper use of opioids concerning the prescribed dosing and avoiding the risk of abuse.

For a better understanding of the market adoption of Oxycodone, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR in the forecast period (2024-2032) because the region is currently witnessing economic growth; hence, there has been enhanced development of health facilities and enhanced availability of medical treatments, including therapies to manage pain. The Asia Pacific region is also growing in the production of pharmaceutical products, and several local and multinational companies are engaged in the production and marketing of opioid drugs. Thus, with the development of chronic pain conditions such as cancer and diabetes and an aging population, China, India, and Japan are the most affected nations.

Some of the major players operating in the market include Purdue Pharma L.P.; Johnson & Johnson Services, Inc.; Teva Pharmaceutical Industries Ltd; Endo, Inc.; Mallinckrodt company; Lannett; Pfizer Inc.; Amneal Pharmaceuticals LLC; Indivior PLC; Teikoku Seiyaku Co., Ltd.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Oxycodone Market
  • 2.2. Research Methodology of the Oxycodone Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL OXYCODONE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY TYPE

  • 7.1. Long-acting oxycodone
  • 7.2. Short-acting oxycodone

8.MARKET INSIGHTS BY APPLICATION

  • 8.1. Pain Management
  • 8.2. De-addiction

9.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Online Pharmacies

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. France
    • 10.2.3. UK
    • 10.2.4. Spain
    • 10.2.5. Italy
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of APAC
  • 10.4. Rest of the World

11.VALUE CHAIN ANALYSIS

  • 11.1. Marginal Analysis
  • 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

  • 13.1. Purdue Pharma L.P.
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Johnson & Johnson Services, Inc.
  • 13.3. Teva Pharmaceutical Industries Ltd
  • 13.4. Endo, Inc.
  • 13.5. Mallinckrodt company
  • 13.6. Lannett
  • 13.7. Pfizer Inc.
  • 13.8. Amneal Pharmaceuticals LLC
  • 13.9. Indivior PLC
  • 13.10. Teikoku Seiyaku Co.,Ltd.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE